Artboard 11

Alice Assinger is the new director of the Ludwig Boltzmann Institute for Cardiovascular Research

On 1 January 2026, Alice Assinger took over as director of the Ludwig Boltzmann Institute (LBI) for Cardiovascular Research and will focus on prevention and gender-specific differences in cardiovascular health.

University Professor, MSc, MSc, Ph.D. Alice Assinger (44) has been the new head of the Ludwig Boltzmann Institute for Cardiovascular Research (LBI) since the beginning of the year. The university professor of cardiovascular medicine at the Medical University of Vienna (MedUni) succeeds Johann Wojta, who headed the institute for over 16 years. With her work at the LBI for Cardiovascular Research, Assinger aims to gain a better understanding of cardiovascular diseases, identify risks at an early stage and make a lasting contribution to prevention.

‘At the Ludwig Boltzmann Institute for Cardiovascular Research, we want to strengthen the bridge between the laboratory and medical application,’ says Alice Assinger, the new director of the LBI for Cardiovascular Research. ‘Working closely with clinical partners, hospitals and preventive care centres, it is my primary concern to quickly transfer research results into clinical practice – with a particular focus on prevention and gender-specific aspects. I look forward to pursuing this path together with a dedicated team.’

Interdisciplinary career and cardiovascular research

Assinger studied nutritional science, microbiology and genetics, and obtained her doctorate in nutritional science from the University of Vienna. She then worked as a postdoctoral researcher at MedUni Vienna before continuing her research at the Karolinska Institute in Stockholm.

Back in Vienna, the Carinthia-born scientist founded a research group focusing on the interaction between thrombocytes and the immune system – a topic whose importance became particularly apparent during the COVID-19 pandemic. In addition to her new role as LBI Director, Alice Assinger has been Professor of Cardiovascular Medicine at MedUni Vienna since 2023.

Zudem betreut die neue LBI-Leiterin Nachwuchswissenschaftler:innen als Supervisorin von Postdocs, Doktorand:innen sowie Master- und Diplomarbeiten. 2018 hat sie ein Patent zu microRNA-Signaturen zur Vorhersage von Leberfunktionsstörungen angemeldet. Darüber hinaus engagiert sich Alice Assinger als Mentorin im „Women’s Network in Medicine“, das hochqualifizierte Wissenschaftlerinnen auf ihrem Karriereweg gezielt fördert.

In ihrer Arbeit am LBI für Kardiovaskuläre Forschung konzentriert sich Assinger mit ihrem Forschungsteam auf zentrale Fragestellungen rund um Herz- und Gefäßerkrankungen. Ein weiterer Schwerpunkt liegt auf dem Verständnis der biologischen Reaktionen des Körpers auf medizinische Implantate, pathologische Veränderungen des Herzens und der Gefäße sowie der frühzeitigen Identifikation potenzieller, kardiovaskulärer Risiken. Dabei setzt das Team auf modernste Technologien wie KI-gestützte Datenanalysen, Wearables und innovative Biomarker-Ansätze. Ziel ist die Entwicklung neuer prädiktiver Marker, die eine frühzeitige Risikoerkennung ermöglichen, Therapien präzisieren und geschlechtsspezifische Unterschiede in der Herz-Kreislauf-Gesundheit systematisch berücksichtigen.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.